Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Update on Janus kinase antagonists in inflammatory bowel disease.

Boland BS, Sandborn WJ, Chang JT.

Gastroenterol Clin North Am. 2014 Sep;43(3):603-17. doi: 10.1016/j.gtc.2014.05.011. Epub 2014 Jun 24. Review.

2.

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.

Danese S, Grisham M, Hodge J, Telliez JB.

Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G155-62. doi: 10.1152/ajpgi.00311.2015. Epub 2015 Nov 25. Review.

3.

Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.

Vuitton L, Koch S, Peyrin-Biroulet L.

Curr Drug Targets. 2013 Nov;14(12):1385-91. Review.

PMID:
23627915
4.

[JAK inhibitor].

Yamaoka K, Tanaka Y.

Nihon Rinsho. 2013 Jul;71(7):1243-7. Review. Japanese.

PMID:
23961674
5.

Tofacitinib for the treatment of ulcerative colitis.

Izzo R, Bevivino G, Monteleone G.

Expert Opin Investig Drugs. 2016 Aug;25(8):991-7. doi: 10.1080/13543784.2016.1189900. Epub 2016 May 30. Review.

PMID:
27177233
6.

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Coskun M, Salem M, Pedersen J, Nielsen OH.

Pharmacol Res. 2013 Oct;76:1-8. doi: 10.1016/j.phrs.2013.06.007. Epub 2013 Jul 2. Review.

PMID:
23827161
7.

Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.

Vyas D, O'Dell KM, Bandy JL, Boyce EG.

Ann Pharmacother. 2013 Nov;47(11):1524-31. doi: 10.1177/1060028013512790. Review.

PMID:
24285764
8.

Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.

Yamaoka K, Tanaka Y.

Expert Opin Pharmacother. 2014 Jan;15(1):103-13. doi: 10.1517/14656566.2014.854771. Epub 2013 Nov 5. Review.

PMID:
24188100
9.

Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.

Fukuyama T, Tschernig T, Qi Y, Volmer DA, Bäumer W.

Eur J Pharmacol. 2015 Oct 5;764:278-82. doi: 10.1016/j.ejphar.2015.06.060. Epub 2015 Jul 9.

PMID:
26164790
10.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators..

N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.

PMID:
28467869
11.

Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis.

Sonomoto K, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(6):443-7. doi: 10.2177/jsci.38.443. Review.

12.

JAK inhibitors in dermatology: The promise of a new drug class.

Damsky W, King BA.

J Am Acad Dermatol. 2017 Apr;76(4):736-744. doi: 10.1016/j.jaad.2016.12.005. Epub 2017 Jan 28. Review.

PMID:
28139263
13.

[A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].

Varisco PA, So A.

Rev Med Suisse. 2014 Jan 22;10(414):187-91. French.

PMID:
24624736
14.

Janus kinase inhibitors in dermatology: A systematic review.

Shreberk-Hassidim R, Ramot Y, Zlotogorski A.

J Am Acad Dermatol. 2017 Apr;76(4):745-753.e19. doi: 10.1016/j.jaad.2016.12.004. Epub 2017 Feb 4. Review.

PMID:
28169015
15.

[Tofacitinib].

Döker S, Dewenter M, El-Armouche A.

Dtsch Med Wochenschr. 2014 May;139(19):1003-8. doi: 10.1055/s-0034-1369986. Epub 2014 Apr 29. Review. German.

PMID:
24782154
16.

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):318-28. Epub 2016 Mar 10. Review.

17.

Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.

Clark JD, Flanagan ME, Telliez JB.

J Med Chem. 2014 Jun 26;57(12):5023-38. doi: 10.1021/jm401490p. Epub 2014 Jan 23. Review.

PMID:
24417533
18.

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

Scott LJ.

Drugs. 2013 Jun;73(8):857-74. doi: 10.1007/s40265-013-0065-8. Review. Erratum in: Drugs. 2013 Sep;73(14):1647.

PMID:
23716132
19.

Promising new treatments for rheumatoid arthritis - the kinase inhibitors.

Yazici Y, Regens AL.

Bull NYU Hosp Jt Dis. 2011;69(3):233-7. Review.

20.

Supplemental Content

Support Center